I did not listen to the CC, I usually don't so that is not unusual. Right now I can get so much more bang for my $$. I never overload any position so I'm comfortable waiting to see how it turns out. The 25% shortage of evaluated patients versus enrolled, but as I remember they increased the enrollment towards the end of the trial so they may not have had time to get the extra enrollees evaluated.
Market Data 
Markets 
AI
